Erste Group upgraded Amgen (AMGN) to Buy from Hold. The firm says Amgen has a higher operating margin and return on equity than the sector average. In addition, the company’s MariTide is the first obesity treatment with monthly or less frequent dosing to demonstrate safe weight loss in a Phase 2 study, the analyst tells investors in a research note. Erste sees a “favorable” valuation at current share levels.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: